EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Bedaquiline, Delamanid, Linezolid, and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis

Chandrasekaran Padmapriyadarsini, Vikram Vohra, Anuj Bhatnagar, Rajesh Solanki, Rathinam Sridhar, Lalitkumar Anande, M Muthuvijaylakshmi, Miraa Bhatia, Bharathi Jeyadeepa, Gaurav Taneja, S Balaji, Prashant Shah und 10 weitere

Clinical Infectious Diseases · 08.02.2023 · 76 (3) · e938-e946

DOI: 10.1093/cid/ciac528 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 29.06.2022. Verfasst von Chandrasekaran Padmapriyadarsini und 21 weiteren Autor:innen. Beteiligte Einrichtung: ICMR-National Institute for Research in Tuberculosis, Chennai, India. Die Arbeit wurde bisher 112-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: World Health Organization, US Agency for International Development, Indian Council of Medical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Treatment success rates for multidrug-resistant tuberculosis (MDR-TB) remain low globally. Availability of newer drugs has given scope to develop regimens that can be patient-friendly, less toxic, with improved outcomes. We proposed to determine the effectiveness of an entirely oral, short-course regimen with bedaquiline and delamanid in treating MDR-TB with additional resistance to fluoroquinolones (MDR-TBFQ+) or second-line injectable (MDR-TBSLI+).

Methods

We prospectively determined the effectiveness and safety of combining 2 new drugs with 2 repurposed drugs—bedaquiline, delamanid, linezolid, and clofazimine—for 24–36 weeks in adults with pulmonary MDR-TBFQ+ and/or MDR-TBSLI+. The primary outcome was a favorable response at end of treatment, defined as 2 consecutive negative cultures taken 4 weeks apart. The unfavorable outcomes included bacteriologic or clinical failure during the treatment period.

Results

Of the 165 participants enrolled, 158 had MDR-TBFQ+. At the end of treatment, after excluding 12 patients due to baseline drug susceptibility and culture negatives, 139 of 153 patients (91%) had a favorable outcome. Fourteen patients (9%) had unfavorable outcomes: 4 deaths, 7 treatment changes, 2 bacteriological failures, and 1 withdrawal. During treatment, 85 patients (52%) developed myelosuppression, 69 (42%) reported peripheral neuropathy, and none had QTc(F) prolongation >500 ms. At 48 weeks of follow-up, 131 patients showed sustained treatment success with the resolution of adverse events in the majority.

Conclusions

After 24–36 weeks of treatment, this regimen resulted in a satisfactory favorable outcome in pulmonary MDR-TB patients with additional drug resistance. Cardiotoxicity was minimal, and myelosuppression, while common, was detected early and treated successfully. Clinical Trials Registration ClinicalTrials Registry of India (CTRI/2019/01/017310).

Schlagwörter

Stichwörter der Autor:innen

DelamanidDrug-resistant TuberculosisEffectivenessLinezolidShort-course

Autor:innen und Institutionen

  • ICMR-National Institute for Research in Tuberculosis, Chennai, India.
  • National Institute for Tuberculosis and Respiratory Diseases, New Delhi, India.
  • Rajan Babu Institute of Pulmonary Medicine and Tuberculosis, Delhi, India.
  • B.J.Medical College and Hospital, Ahmedabad, India.
  • Government Hospital of Thoracic Medicine, Chennai, India.
  • Grand TB Hospital, Mumbai, India.

Förderung

  • World Health Organization
  • US Agency for International Development
  • Indian Council of Medical Research

Zitieren

APA

Padmapriyadarsini, C., Vohra, V., Bhatnagar, A., Solanki, R., Sridhar, R., Anande, L., Muthuvijaylakshmi, M., Bhatia, M., Jeyadeepa, B., Taneja, G., Balaji, S., Shah, P., Saravanan, N., Chauhan, V., Kumar, H., Ponnuraja, C., Livchits, V., Bahl, M., Alavadi, U., …, & for BEAT India Team (2023). Bedaquiline, Delamanid, Linezolid, and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis. Clinical Infectious Diseases, 76(3), e938-e946. https://doi.org/10.1093/cid/ciac528

Vancouver

Padmapriyadarsini C, Vohra V, Bhatnagar A, Solanki R, Sridhar R, Anande L, et al. Bedaquiline, Delamanid, Linezolid, and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis. Clinical Infectious Diseases. 2023;76(3):e938-e946. doi:10.1093/cid/ciac528

BibTeX
@article{Padmapriyadarsini2023,
  author = {Padmapriyadarsini, Chandrasekaran and Vohra, Vikram and Bhatnagar, Anuj and Solanki, Rajesh and Sridhar, Rathinam and Anande, Lalitkumar and Muthuvijaylakshmi, M and Bhatia, Miraa and Jeyadeepa, Bharathi and Taneja, Gaurav and Balaji, S and Shah, Prashant and Saravanan, N and Chauhan, Vijay and Kumar, Hemanth and Ponnuraja, Chinnayin and Livchits, Viktoriya and Bahl, Monica and Alavadi, Umesh and Sachdeva, K S and Swaminathan, Soumya and for BEAT India Team, for BEAT India Team},
  title = {Bedaquiline, Delamanid, Linezolid, and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  volume = {76},
  number = {3},
  pages = {e938--e946},
  doi = {10.1093/cid/ciac528}
}
Kostenlos starten →